Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 27;16(7):1969-1972.
doi: 10.4240/wjgs.v16.i7.1969.

Impact of immunotherapy on liver metastasis

Zhuo Fu  1 , Ming-Wei Wang  2 , Ya-Hui Liu  3 , Yan Jiao  4
Affiliations
Editorial

Impact of immunotherapy on liver metastasis

Zhuo Fu et al. World J Gastrointest Surg. .

Abstract

This editorial discusses the article "Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis" published in the latest edition of the World Journal of Gastrointestinal Surgery. Immunotherapy has achieved outstanding success in tumor treatment. However, the presence of liver metastasis (LM) restrains the efficacy of immunotherapy in various tumors, including lung cancer, colorectal cancer, renal cell carcinoma, melanoma, and gastric cancer. A decrease in CD8+ T cells and nature killer cells, along with an increase in macrophages and regulatory T cells, was observed in the microenvironment of LM, leading to immunotherapy resistance. More studies are necessary to determine the best strategy for enhancing the effectiveness of immunotherapy in patients with LM.

Keywords: Immunotherapy; Liver metastasis; Resistance; T cells; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1
Figure 1
The suppressive immune microenvironment of liver metastasis. The figure was created with Figdraw (www.figdraw.com).
See this image and copyright information in PMC

References

    1. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–821. - PMC - PubMed
    1. Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37:443–455. - PMC - PubMed
    1. Majidpoor J, Mortezaee K. Steps in metastasis: an updated review. Med Oncol. 2021;38:3. - PubMed
    1. Park JH, Kim JH. Pathologic differential diagnosis of metastatic carcinoma in the liver. Clin Mol Hepatol. 2019;25:12–20. - PMC - PubMed
    1. Yin WJ, Ma SC, Dong ZY, Xu M, Mao W. Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy. Cancer Manag Res. 2021;13:4541–4551. - PMC - PubMed

Publication types